Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD

0.5342  +0.01 (+1.71%)

After market: 0.546 +0.01 (+2.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VERU. VERU was compared to 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of VERU have multiple concerns. VERU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VERU had negative earnings in the past year.
VERU had a negative operating cash flow in the past year.
VERU had negative earnings in 4 of the past 5 years.
In the past 5 years VERU always reported negative operating cash flow.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

VERU has a worse Return On Assets (-62.57%) than 67.17% of its industry peers.
The Return On Equity of VERU (-116.97%) is worse than 61.11% of its industry peers.
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 34.66%, VERU perfoms like the industry average, outperforming 56.57% of the companies in the same industry.
VERU's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VERU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERU has more shares outstanding
Compared to 5 years ago, VERU has more shares outstanding
The debt/assets ratio for VERU has been reduced compared to a year ago.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.50, we must say that VERU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VERU (-6.50) is worse than 66.67% of its industry peers.
VERU has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
VERU's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. VERU outperforms 44.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC9.7%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

VERU has a Current Ratio of 2.97. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
VERU has a Current ratio (2.97) which is in line with its industry peers.
A Quick Ratio of 2.62 indicates that VERU has no problem at all paying its short term obligations.
VERU has a Quick ratio of 2.62. This is comparable to the rest of the industry: VERU outperforms 54.55% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.62
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.90% over the past year.
VERU shows a small growth in Revenue. In the last year, the Revenue has grown by 3.62%.
VERU shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.89% yearly.
EPS 1Y (TTM)67.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

VERU is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.30% yearly.
The Revenue is expected to grow by 60.53% on average over the next years. This is a very strong growth
EPS Next Y17.67%
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%
EPS Next 5Y1.3%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -8.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%

More info and screens

0

5. Dividend

5.1 Amount

VERU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (4/17/2025, 8:00:02 PM)

After market: 0.546 +0.01 (+2.21%)

0.5342

+0.01 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners35.42%
Inst Owner Change0.19%
Ins Owners10.62%
Ins Owner Change1.53%
Market Cap78.20M
Analysts81.82
Price Target2.81 (426.02%)
Short Float %11.51%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.09%
Min EPS beat(2)-18.32%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-0.6%
Min EPS beat(4)-28.68%
Max EPS beat(4)24.1%
EPS beat(8)4
Avg EPS beat(8)3.01%
EPS beat(12)5
Avg EPS beat(12)-7.96%
EPS beat(16)8
Avg EPS beat(16)4.03%
Revenue beat(2)2
Avg Revenue beat(2)47.04%
Min Revenue beat(2)10.75%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)22.02%
Min Revenue beat(4)-41.15%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)1.72%
Revenue beat(12)6
Avg Revenue beat(12)-8.13%
Revenue beat(16)8
Avg Revenue beat(16)-3.95%
PT rev (1m)-14.06%
PT rev (3m)-19.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.33%
EPS NY rev (1m)0%
EPS NY rev (3m)21.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.91%
Revenue NY rev (1m)-14.21%
Revenue NY rev (3m)-68.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.63
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 3.07
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.12
BVpS0.22
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.57%
ROE -116.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.66%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.02%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.62
Altman-Z -6.5
F-Score4
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y17.67%
EPS Next 2Y-0.39%
EPS Next 3Y-8.95%
EPS Next 5Y1.3%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%
EBIT growth 1Y61.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.36%
OCF growth 3YN/A
OCF growth 5YN/A